Phaseline

Targets › VIM

VIM (Vimentin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. (UniProt, P08670)

Open in Phaseline: the race on VIM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
FilamonKESONOTIDE™
hGIIA-Vimentin inhibitor
VIMPhase 1Prostate CancersOct 2027

Conditions

Prostate Cancers (1)

Modalities

small molecule (1)

Companies

Filamon (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.